Galactooligosaccharides (GOS) ： Irritable Bowel Syndrome (IBS)

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dgalactooligosaccharides\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

Key Study Findings

Review

Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal …

Dose: None vs: None Outcome: None 効果: None None

対象集団: review of prebiotics, probiotics, synbiotics, postbiotics for gastrointestinal inflammation

Randomized Controlled Trial n=45 12 weeks Double-blind

All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable …

Dose: None vs: Sequential FODMAP subgroup reintroduction Outcome: Abdominal pain and bloating severity 効果: None p=0.007 fructans; p=0.04 GOS

対象集団: IBS patients (Rome IV) who improved on FODMAP diet

Randomized Controlled Trial 4 weeks Double-blind

Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized …

Dose: None vs: Traditional low FODMAP diet Outcome: IBS symptom response 効果: None None

対象集団: IBS-D patients (Rome IV)

Systematic Review

Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews …

Dose: None vs: Various Outcome: IBS symptom improvement 効果: Probiotics abdominal pain RR 4.04 (2.36-6.92) None

対象集団: Adult IBS patients

Randomized Controlled Trial n=34 8 weeks Single-blind

A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation …

Dose: 9.2 g/day total (4.6 g twice daily) vs: Maltodextrin 9.2 g/day placebo Outcome: IBS-SSS score and IBS-QoL score 効果: IBS-SSS: 267.3→195.8; IBS-QoL: 61.0→77.4 0.026 (IBS-SSS); 0.006 (QoL)

対象集団: Adults with constipation-predominant IBS

Other

Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.

Dose: None vs: Standard wholegrain flour products Outcome: FODMAP content reduction in cookies and crackers 効果: Up to 99.5% FODMAP reduction (wheat malt) None

対象集団: Laboratory food science study (no human subjects)

Key Statistics

研究数

400

参加者数

↑

Positive

グレード

Referenced Papers

Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal inflammation. Review

Food research international … 2026

Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized Controlled Trial. RCT

Clinical gastroenterology and … 2025 19 件の引用

All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome. RCT

Clinical gastroenterology and … 2025 12 件の引用

Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Clinical … Systematic Review

Nutrition reviews 2025 10 件の引用

Lactobacillus plantarum and Galacto-Oligosaccharides Synbiotic Relieve Irritable Bowel Syndrome by Reshaping Gut Microbiota and Attenuating Mast Cell Hyperactivation. Other

Nutrients 2025 6 件の引用

FODMAP Profile of Wholegrain Pasta. Other

Foods (Basel, Switzerland) 2025 3 件の引用

A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS. RCT

Scientific reports 2025 2 件の引用

Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. Other

Foods (Basel, Switzerland) 2025 1 件の引用

Clinical Applications of Bovine Colostrum in GastrointestinaI Disorders: Mechanisms, Evidence, and Therapeutic Potential. Review

International journal of … 2025

Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. Other

Gastroenterology research and … 2025

A non-pharmacological intervention for insomnia: tryptophan-fructooligosaccharides combination improves sleep in mice via anti-inflammation and gut microbiota modulation. Other

Food & function 2025

Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. RCT

Gastroenterology 2024 24 件の引用

FODMAP reduction strategies for nutritionally valuable baking products: current state and future challenges. Review

Critical reviews in … 2024 7 件の引用

Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … Other

Journal of clinical … 2024 4 件の引用

Postbiotics: A new member in the biotics family. Other

Archivos argentinos de … 2024 3 件の引用

Laboratory domestication of Lactiplantibacillus plantarum alters some phenotypic traits but causes non-novel genomic impact. Other

Journal of applied … 2024 1 件の引用

Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Other

Gastro hep advances 2024 1 件の引用

Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. Other

Frontiers in nutrition 2023 8 件の引用

Food contributing to fermentable oligosaccharide, disaccharide, monosaccharide, and polyols intake in Korean adults. Other

Nutrition research and … 2023 2 件の引用

[Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … Other

Voprosy pitaniia 2023

Inulin as a functional ingredient and their applications in meat products. Review

Carbohydrate polymers 2022 77 件の引用

Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome. Review

American journal of … 2022 18 件の引用

Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. Other

FASEB journal : … 2022 16 件の引用

Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … Other

Journal of clinical … 2022 12 件の引用

The challenges of implementing low fermentable oligo-, di-, mono-saccharides and polyol diet in India: An analysis of available data. Other

Indian journal of … 2022 11 件の引用

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … RCT

Nutrients 2022 8 件の引用

Current evidence on the therapeutic use of fiber in irritable bowel syndrome. Other

Expert review of … 2022 8 件の引用

Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. Other

Food chemistry: X 2021 64 件の引用

Best management of irritable bowel syndrome. Review

Frontline gastroenterology 2021 56 件の引用

The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel … RCT

Nutrients 2021 36 件の引用

FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. Other

Foods (Basel, Switzerland) 2021 10 件の引用

FODMAP Consumption by Adults from the French Population-Based NutriNet-Santé Cohort. Other

The Journal of … 2021 6 件の引用

Dietary interventions and irritable bowel syndrome - what really works? Review

Current opinion in … 2021 6 件の引用

A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … RCT

Neurogastroenterology and motility 2021 4 件の引用

Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease … RCT

Gastroenterology 2020 290 件の引用

The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … RCT

Nutrients 2020 78 件の引用

β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. RCT

The American journal … 2020 75 件の引用

Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. CCT

Nutrition research (New … 2020 42 件の引用

Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Other

Gastroenterology 2020 41 件の引用

Variability in yeast invertase activity determines the extent of fructan hydrolysis during wheat dough fermentation and final FODMAP levels in … Other

International journal of … 2020 30 件の引用

Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? RCT

European journal of … 2020 20 件の引用

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). Other

Journal of the … 2019 171 件の引用

Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled … Meta-Analysis

The American journal … 2019 108 件の引用

Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to … Review

Alimentary pharmacology & … 2019 36 件の引用

Processing methods for reducing alpha-galactosides in pulses. Review

Critical reviews in … 2019 35 件の引用

Technological Methods for Reducing the Content of Fructan in Wheat Bread. Other

Foods (Basel, Switzerland) 2019 21 件の引用

Influence of Dietary Restriction on Irritable Bowel Syndrome. Review

The American journal … 2019 15 件の引用

Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. RCT

Clinical gastroenterology and … 2018 100 件の引用

Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. RCT

The American journal … 2018 49 件の引用

Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). Other

Journal of agricultural … 2018 13 件の引用

Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. Review

Journal of gastroenterology … 2017 255 件の引用

FODMAPs: food composition, defining cutoff values and international application. Review

Journal of gastroenterology … 2017 181 件の引用

Dietary fiber in irritable bowel syndrome (Review). Other

International journal of … 2017 146 件の引用

Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … RCT

Neurogastroenterology and motility 2017 131 件の引用

Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. RCT

Journal of Crohn's … 2017 122 件の引用

When the low FODMAP diet does not work. Review

Journal of gastroenterology … 2017 32 件の引用

Irritable bowel syndrome and diet: where are we in 2018? Review

Current opinion in … 2017 24 件の引用

Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. RCT

Nutrition journal 2017 10 件の引用

Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome? Other

Alimentary pharmacology & … 2017

Diet and nutritional factors in inflammatory bowel diseases. Review

World journal of … 2016 238 件の引用

Does oral α-galactosidase relieve irritable bowel symptoms? RCT

Scandinavian journal of … 2016 17 件の引用

[Non-allergic gluten sensitivity. A controversial disease - or not yet sufficiently explored?]. Other

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2016 2 件の引用

The Low FODMAP Diet and Its Application in East and Southeast Asia. Other

Journal of neurogastroenterology … 2015 60 件の引用

Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. RCT

The Journal of … 2012 558 件の引用

Health benefits of probiotics and prebiotics in women. Review

Menopause international 2009 29 件の引用

Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized … RCT

Journal of clinical … 2008 73 件の引用

Review article: prebiotics in the gastrointestinal tract. Review

Alimentary pharmacology & … 2006 629 件の引用

Beneficial health effects of low-digestible carbohydrate consumption. Review

The British journal … 2001 166 件の引用

Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. RCT

The American journal … 2000 136 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:: 2.5-5 g/day
ibssupport:: 3.5 g/day (optimal dose; higher doses may increase symptoms)
infantgutsupport:: 0.24-0.48 g/100 mL formula (added to infant formula)

上限量： Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

研究で検討された用量

用量	期間	効果	N
None	--	Positive	--
None	12 weeks	Negative	45
None	4 weeks	Mixed	--
None	--	Positive	--
9.2 g/day total (4.6 g twice daily)	8 weeks	Positive	34
None	--	Positive	--
1e9 CFU/day + GOS 10 g/L	--	Positive	--
None	--	Neutral	--

推奨摂取タイミング： With meals; start with lower dose and increase gradually

Safety & Side Effects

報告されている副作用

⚠ Gas and bloating (especially above 5 g/day; dose-response is U-shaped)
⚠ Flatulence at higher doses
⚠ Abdominal cramping if dose increased too quickly
⚠ May worsen symptoms in FODMAP-sensitive individuals

既知の相互作用

● Other FODMAPs (cumulative fermentation in sensitive individuals)
● Lactose-containing products (GOS is derived from lactose; generally safe for lactose-intolerant individuals as GOS itself is lactose-free)

耐容上限摂取量： Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Galactooligosaccharides (GOS) help with Irritable Bowel Syndrome (IBS)?

Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Galactooligosaccharides (GOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).

How much Galactooligosaccharides (GOS) should I take for Irritable Bowel Syndrome (IBS)?

Studies have used various dosages. A commonly studied range is 2.5-5 g/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Galactooligosaccharides (GOS)?

Reported side effects may include Gas and bloating (especially above 5 g/day; dose-response is U-shaped), Flatulence at higher doses, Abdominal cramping if dose increased too quickly, May worsen symptoms in FODMAP-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Galactooligosaccharides (GOS) and Irritable Bowel Syndrome (IBS)?

We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分： Irritable Bowel Syndrome (IBS)

Peppermint Oil A Lactobacillus rhamnosus GG B Psyllium Husk B Lactobacillus plantarum B Partially Hydrolyzed Guar Gum (PHGG) B Bifidobacterium longum B

総合評価

Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).

Evidence Strength72%

High confidence

研究の内訳

RCT (20)Meta (1)Other (0)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Irritable Bowel Syndrome (IBS)

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。